Introduction {#sec1}
============

Quinazolin-4-ones are an important class of heterocyclic structural scaffolds that have been found in many natural products^[@ref1]^ and bioactive compounds.^[@ref2]^ For example, the natural alkaloids of luotonin A and luotonin F and the marketing drugs of piriqualone and methapualone are the derivatives of quinazolin-4-one ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). In addition, quinazolin-4-ones are also the important intermediates for the synthesis of other nitrogen heterocyclic compounds having physiological and biological activity.^[@ref3]^

![Selected Naturally Found Alkaloids and Drugs with the Quinazolinone Skeleton](ao-2019-00699f_0002){#sch1}

Therefore, the chemistry and the synthetic strategies for constructing the quinazolin-4-one ring have been well investigated.^[@ref4]^ Among them, the most common and practical synthetic methods are intermolecular annulation using *ortho*-aminobenzamides or *ortho*-halobenzamides as starting materials.^[@ref5],[@ref6]^ For example, quinazolin-4-one derivatives can be obtained from the cyclocondensation of *ortho*-aminobenzamides with aldehydes catalyzed either by copper salts in dimethylacetamide^[@cit5b]^ or by bis-sulfonated ionic liquids via aerobic oxidative reaction in water or ethanol^[@cit5j]^ or by aerobic oxidative reaction in wet dimethyl sulfoxide (DMSO).^[@cit5d]^ The reactions of *ortho*-aminobenzamide with primary alcohols in dimethyl carbonate catalyzed by iodine with the use of DMSO as the oxidant^[@cit5c]^ or with 1,3-diketones in aqueous ethyl lactate catalyzed by camphorsulfonic acid^[@cit5h]^ or with isocyanides and arylboronic acids in dimethylformamide (DMF) catalyzed by PdCl~2~(PPh~3~)~2~ with the use of Cu(OAc)~2~ as the oxidant^[@cit5k]^ can also afford quinazolin-4-ones. In addition, the syntheses of quinazolin-4-ones from the intermolecular annulation of *ortho*-halobenzamides are shown in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. It involves the reaction of *ortho*-halobenzamides with benzylamines^[@cit6a]^ or amino acids^[@cit6b]^ in DMSO catalyzed by CuBr using air as the oxidant, the reaction of N-substituted *ortho*-bromobenzamides with formamide in DMF catalyzed by CuI/4-hydroxy-[l]{.smallcaps}-proline,^[@cit6c]^*ortho*-bromobenzamides with aldehydes and aqueous ammonia in DMSO catalyzed by CuBr/[l]{.smallcaps}-proline using Cs~2~CO~3~ as the base and air as the oxidant^[@cit6d]^ or with the use of Cu--Mn spinel oxide as a heterogeneous catalyst,^[@cit6f]^*ortho*-iodobenzamides with benzylamines or cinnamylamines in DMSO catalyzed by copper salts with the use of K~2~CO~3~ as the base and air as the oxidant,^[@cit6e]^*ortho*-bromobenzamides with aldehydes or alcohols, or methyl arenes catalyzed by CuI in DMSO in the presence of the oxidant and using TMSN~3~ as a nitrogen source,^[@cit6g]^*ortho*-bromobenzamides with benzylic alcohols and sodium azide catalyzed by CuO/[l]{.smallcaps}-proline in DMF with the use of 2,2,6,6-tetramethylpiperidine-1-oxyl as the oxidant and TsOH·H~2~O as the additive,^[@cit6h]^ and *ortho*-halobenzamides with nitriles catalyzed by Cu(OAc)~2~ in the presence of ^*t*^BuOK as the base.^[@cit6i]^ On the basis of the above-described procedures for the construction of the quinazolin-4-one ring from *ortho*-halobenzamides as starting materials, it is readily apparent and interesting to find that, besides the requirement of copper catalysts, in most cases, DMSO is used as the solvent, and inorganic bases are employed as additives.

![Synthesis of Quinazolin-4-ones from *ortho*-Halobenzamides](ao-2019-00699f_0003){#sch2}

On the other hand, inorganic base/DMSO medium have been well applied to promote the nucleophilic haloarenes substitution of the C--X bond for the formation of the C--N bond and the synthesis of nitrogen heterocyclic compounds.^[@ref7]^ In the continuation of our interest in developing the efficient methods for the synthesis of nitrogen heterocyclic compounds^[@ref8]^ and the application of base/DMSO-promoted S~N~Ar reaction for the formation of the C--N bond,^[@cit7g]^ we herein would like to report a new approach to the construction of the quinazolin-4-one ring under transition-metal-free conditions, which involves the base-promoted S~N~Ar reaction of *ortho*-fluorobenzamides with amides followed by cyclization ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).

Results and Discussion {#sec2}
======================

Fu's group developed a CuBr-catalyzed synthesis of quinazolinones via the reaction of 2-iodo/bromobenzamides with benzylamines in DMSO using K~2~CO~3~ as the base;^[@cit6a]^ thus, we first carried out the reaction of 2-fluoro-*N*-methylbenzamide (**1a**) with benzamide (**2a**, 2.5 equiv) in the presence of K~2~CO~3~ (4.0 equiv) in DMSO. After 24 h at 135 °C, on the basis of the analysis of the reaction mixture by gas chromatography--mass spectrometry (GC--MS), only a trace amount of 3-methyl-2-phenylquinazolin-4-one (**3aa**) was formed ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). The reaction was then repeated in the presence of KOH (4.0 equiv) because Bolm's group established intramolecular N-arylations of *N*-(2-haloaryl)ureas to form benzimidazol-2-ones under the conditions of KOH (2.0 equiv)/DMSO;^[@ref9]^**3aa** can be isolated from the reaction mixture in 10% yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 2), and in this case, the considerable amount of 2-hydroxy-*N*-methylbenzamide formed via the S~N~Ar reaction of **1a** with KOH. The use of KO^*t*^Bu resulted in the similar yield of **3aa** as KOH employed ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 3). Fortunately, when Cs~2~CO~3~ was used in DMSO, **3aa** could be obtained in 72% isolated yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 4),^[@ref10]^ although the yields of **3aa** were not satisfactory in other solvents, such as tetrahydrofuran (THF), 1,4-dioxane, and DMF ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 5--7). The decrease of either **2a** (2.5 equiv to 1.5--1.0 equiv) or Cs~2~CO~3~ (4.0 equiv to 1.0--0.5 equiv) resulted in the considerable decrease of yields ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 8--11). In addition, it was found that 2.5 equiv of Cs~2~CO~3~ was suitable for the present transformation as a similar and good yield of **3aa** was achieved (70%, entry 12 vs entry 4). As expected, Cs~2~CO~3~ is found to be the essential promoter for the formation of **3aa** in DMSO because its absence led to no **3aa** formation at all ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 13).

###### Optimization of Reaction Conditions for Quinazolin-4-one Synthesis[a](#t1fn1){ref-type="table-fn"}

![](ao-2019-00699f_0005){#GRAPHIC-d7e504-autogenerated}

  entry   **2a** (equiv)   base (equiv)       solvent   yield (%)[b](#t1fn2){ref-type="table-fn"}
  ------- ---------------- ------------------ --------- -------------------------------------------
  1       2.5              K~2~CO~3~ (4)      DMSO      trace
  2       2.5              KOH (4)            DMSO      10
  3       2.5              KO^*t*^Bu (4)      DMSO      12
  4       2.5              Cs~2~CO~3~ (4)     DMSO      72
  5       2.5              Cs~2~CO~3~ (4)     THF       15
  7       2.5              Cs~2~CO~3~ (4)     dioxane   19
  6       2.5              Cs~2~CO~3~ (4)     DMF       25
  8       1.0              Cs~2~CO~3~ (4)     DMSO      61
  9       1.5              Cs~2~CO~3~ (4)     DMSO      65
  10      2.5              Cs~2~CO~3~ (0.5)   DMSO      33
  11      2.5              Cs~2~CO~3~ (1.0)   DMSO      55
  12      2.5              Cs~2~CO~3~ (2.5)   DMSO      70
  13      2.5                                 DMSO      0

Reactions were carried out using **1a** (1.0 mmol) and **2a**, base in 4.0 mL of solvent in a sealed tube at 135 °C for 24 h.

Yields of **3aa** are isolated.

To evaluate the scope and limitations of the present procedure, the reactions of several *ortho*-fluorobenzamides with a wide variety of amides were examined under the reaction conditions indicated in entry 12 of [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}.

As concluded in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, except for benzamide (**2a**), the annulation of **1a** with other arylamides (**2b--2g**) and heteroaryl amides (**2h**) occurs smoothly to give the corresponding quinazolin-4-one products (**3ab--3ah**) in good isolated yields. *ortho*-Fluorobenzamides bearing either the electron-rich group (OMe, **1b**) or electron-poor group (CF~3~, **1c**) undergoes the annulation reaction affording **3ba**, **3ca**, and **3cc** in acceptable yields. *ortho*-Fluoro-*N*-(*n*-propyl)benzamides (**1d** and **1e**) show good reactivity to undergo the annulation with electron-rich arylamides. In addition, both electron-rich and electron-poor arylamides, as well as heteroaryl amides (**2h** and **2i**) are efficiently annulated with *ortho*-fluorobenzamide (**1f**) to give the corresponding quinazolin-4-one products in good isolated yields (**3fa**, **3fb**, **3fd**, **3fe**, **3fh**, **3fi**, and **3fk**). Note that the annulation reactions of **1a** and **1d** with *ortho*-iodobenzamide (**2f**) or *ortho*-bromobenzamide (**2g**) proceed with high chemoselectivity to give the corresponding quinazolin-4-ones \[**3af**, **3ag**, **3df** (X-ray, see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b00699/suppl_file/ao9b00699_si_001.pdf)), and **3dg**\] via the S~N~Ar reaction of the C--F bond in **1a** and **1d**, while the C--I and C--Br bonds in **2f** and **2g** are untouched. The products having the C--I or C--Br bond are very useful for their further functionalization through carbon--halide bond activation. Moreover, except for (hetero)aryl amides, acetamide (**2j**) was also subjected for annulation reaction with **1a** to give **3aj** in high yields (78%). More importantly, the reaction of 2-fluoro-*N*-(*o*-tolyl)benzamide (**1g**) with **2j** produces **3gf** (methaqualone) in 67% yield, providing an efficient and simple, one-pot protocol for the synthesis of the marketed drug product of methaqualone. In addition, we are also interested in the homocyclodimerization of **1f** under the same reaction conditions, as expected, the reaction occurs smoothly to give **3f** in 92% yield.

###### Substrate Scope of Quinazolin-4-one Synthesis[a](#t2fn1){ref-type="table-fn"}

![](ao-2019-00699f_0006){#GRAPHIC-d7e1018-autogenerated}

![](ao-2019-00699f_0007){#gr4}

Reactions were carried out using **1** (1.0 mmol), **2** (2.5 mmol), and Cs~2~CO~3~ (2.5 mmol) in 4.0 mL of DMSO in a sealed tube at 135 °C for 24 h.

A plausible mechanism for the formation of **3aa** is shown in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}. It involves the S~N~Ar reaction of **1a** with **2a** giving the intermediate of diamide **4aa**, which undergoes the intramolecular nucleophilic addition promoted by the base, and the final dehydration to afford **3aa**. **4aa** can be isolated from a reaction mixture of **1a** and **2a** under the similar reaction conditions as for the formation of **3aa** but after a short reaction time (12h, **4aa** 41%). As expected, **4aa** can be converted into **3aa** in high yields ([eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}).

![Plausible Mechanism for the Formation of Quinazolin-4-one](ao-2019-00699f_0004){#sch3}

Conclusions {#sec3}
===========

In conclusion, we have established a Cs~2~CO~3~-promoted synthesis of quinazolin-4-ones in DMSO through S~N~Ar reaction of *ortho*-fluorobenzamides with amides followed by intramolecular cyclization, providing an alternative protocol for the construction of the quinazolin-4-one ring. The significant advantages of the present procedure include the formation of C--N under transition-metal-free conditions and the direct application in the synthesis of marketed drug of methaqualone.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

All commercial reagents are analytically pure and used without further purification. Nuclear magnetic resonance (NMR) spectra were recorded using CDCl~3~ and DMSO-*d*~6~ at 298 K. ^1^H NMR (400 MHz) chemical shifts (δ) were referenced to internal standard tetramethylsilane (for ^1^H, δ = 0.00 ppm). ^13^C NMR (100 MHz) chemical shifts were referenced to internal solvent CDCl~3~ (for ^13^C, δ = 77.16 ppm) and DMSO-*d*~6~ (for ^13^C, δ = 39.52 ppm). Mass spectra were obtained on a low-resolution GC--MS spectrometer, and high-resolution mass spectrometry (HRMS) spectra were recorded on a high-resolution magnetic sector mass spectrometer with an electrospray ionization (ESI) source. The melting points are uncorrected.

### Typical Experimental Procedure for the Synthesis of 3-Methyl-2-phenylquinazolin-4(3*H*)-one (**3aa**) {#sec4.1.1}

To a 25 mL tube equipped with a magnetic stirrer were added 2-fluoro-*N*-methylbenzamide (**1a**) (153.1 mg, 1.0 mmol), benzamide (**2a**) (302.8 mg, 2.5 mmol), Cs~2~CO~3~ (815.1 mg, 2.5 mmol), and the freshly distilled DMSO (4.0 mL) under nitrogen. The tube was sealed and stirred at 135 °C for 24 h in an oil bath. After the reaction mixture was cooled to room temperature, it was poured into a solvent mixture of water (50.0 mL) and ethyl acetate (20.0 mL), and the two phases were then separated. The aqueous layer was extracted with ethyl acetate (3 × 20.0 mL). The combined organic extracts were dried over anhydrous Na~2~SO~4~. After removal of the solvent under reduced pressure, the residue was purified by column chromatography on silica gel with petroleum ether/ethyl acetate (gradient mixture ratio from 100:0 to 70:30) as the eluent to afford **3aa** as a white solid (165.3 mg, 70%).

### 3-Methyl-2-phenylquinazolin-4(3*H*)-one (**3aa**)^[@cit5k]^ {#sec4.1.2}

It is obtained as a white solid (165.3 mg, 70%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.33 (d, *J* = 7.9 Hz, 1H), 7.81--7.70 (m, 2H), 7.61--7.45 (m, 6H), 3.49 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.8, 156.2, 147.4, 135.5, 134.4, 130.1, 129.0, 128.1, 127.16, 127.6, 126.8, 120.6, 34.3; GC--MS *m*/*z*: 236 (M^+^).

### 3-Methyl-2-(*o*-tolyl)quinazolin-4(3*H*)-one (**3ab**)^[@cit5j]^ {#sec4.1.3}

It is obtained as a white solid (182.7 mg, 73%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.33 (d, *J* = 7.9 Hz, 1H), 7.79--7.26 (m, 2H), 7.49 (t, *J* = 6.4 Hz, 1H), 7.42--7.27 (m, 4H), 3.32 (s, 3H), 2.23 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.4, 156.0, 147.3, 135.2, 135.1, 134.3, 130.7, 129.8, 127.5 (2C), 127.0, 126.7, 126.5, 120.7, 32.7, 19.1; GC--MS *m*/*z*: 250 (M^+^).

### 3-Methyl-2-(*p*-tolyl)quinazolin-4(3*H*)-one (**3ac**)^[@cit5k]^ {#sec4.1.4}

It is obtained as a white solid (187.7 mg, 75%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.30 (d, *J* = 8.0 Hz, 1H), 7.76--7.67 (m, 2H), 7.51--7.42 (m, 3H), 7.31 (d, *J* = 7.9 Hz, 2H), 3.49 (s, 3H), 2.42 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.8, 156.3, 147.4, 140.3, 134.2, 132.6, 129.5, 128.0, 127.5, 126.8, 126.7, 120.5, 34.3, 21.5; GC--MS *m*/*z*: 250 (M^+^).

### 2-(4-Methoxyphenyl)-3-methylquinazolin-4(3*H*)-one (**3ad**)^[@cit6e]^ {#sec4.1.5}

It is obtained as a white solid (154.4 mg, 58%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.32 (d, *J* = 7.9 Hz, 1H), 7.80--7.69 (m, 2H), 7.53 (d, *J* = 8.7 Hz, 2H), 7.49 (t, *J* = 6.9 Hz, 1H), 7.03 (d, *J* = 8.7 Hz, 2H), 3.88 (s, 3H), 3.53 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 163.1, 161.1, 156.1, 147.5, 134.3, 129.9, 127.9, 127.5, 126.9, 126.8, 120.5, 114.3, 55.6, 34.5; GC--MS *m*/*z*: 266 (M^+^).

### 3-Methyl-2-(naphthalen-2-yl)quinazolin-4(3*H*)-one (**3ae**)^[@cit5k]^ {#sec4.1.6}

It is obtained as a white solid (174.6 mg, 61%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.36 (d, *J* = 7.9 Hz, 1H), 8.10 (s, 1H), 8.03--7.88 (m, 3H), 7.77 (d, *J* = 3.8 Hz, 2H), 7.65--7.48 (m, 4H), 3.54 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.9, 156.2, 147.5, 134.4, 133.8, 133.0, 132.8, 128.8, 128.6, 128.2, 127.9, 127.67, 127.62, 127.1 (2C), 126.8, 124.8, 120.7, 34.4; GC--MS *m*/*z*: 286 (M^+^).

### 2-(2-Iodophenyl)-3-methylquinazolin-4(3*H*)-one (**3af**) {#sec4.1.7}

It is obtained as a white solid (246.2 mg, 68%); mp 112--114 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.35 (d, *J* = 8.2 Hz, 1H), 7.94 (d, *J* = 8.0 Hz, 1H), 7.81--7.70 (m, 2H), 7.57--7.47 (m, 2H), 7.41 (d, *J* = 6.3 Hz, 1H), 7.20 (t, *J* = 7.7 Hz, 1H), 3.36 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.3, 156.3, 147.3, 140.7, 139.5, 134.4, 131.1, 128.9, 128.8, 127.7, 127.4, 126.8, 121.0, 95.7, 32.7; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~15~H~11~IN~2~O, 362.9989; found, 362.9993.

### 2-(2-Bromophenyl)-3-methylquinazolin-4(3*H*)-one (**3ag**) {#sec4.1.8}

It is obtained as a white solid (201.7 mg, 64%); mp 139--141 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.34 (d, *J* = 8.1 Hz, 1H), 7.78--7.72 (m, 2H), 7.69 (d, *J* = 8.1 Hz, 1H), 7.53--7.44 (m, 3H), 7.37 (t, *J* = 7.4 Hz, 1H), 3.38 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.2, 154.6, 147.3, 136.7, 134.4, 133.1, 131.3, 129.5, 128.2, 127.6, 127.4, 126.8, 121.6, 121.0, 32.5; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~15~H~11~BrN~2~O, 315.0128; found, 315.0135.

### 7-Methoxy-3-methyl-2-phenylquinazolin-4(3*H*)-one (**3ba**)^[@cit5k]^ {#sec4.1.9}

It is obtained as a white solid (135.8 mg, 51%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.20 (d, *J* = 8.8 Hz, 1H), 7.58--7.48 (m, 5H), 7.11 (s, 1H), 7.06 (d, *J* = 8.8 Hz, 1H), 3.88 (s, 3H), 3.46 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 164.6, 162.3, 156.9, 149.6, 135.6, 130.1, 128.9, 128.3, 128.0, 117.4, 114.1, 107.9, 55.7, 34.1; GC--MS *m*/*z*: 266 (M^+^).

### 3-Methyl-2-phenyl-7-(trifluoromethyl)quinazolin-4(3*H*)-one (**3ca**) {#sec4.1.10}

It is obtained as waxy oil (145.9 mg, 48%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.42 (d, *J* = 8.3 Hz, 1H), 8.01 (s, 1H), 7.68 (d, *J* = 8.3 Hz, 1H), 7.60--7.52 (m, 5H), 3.52 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.1, 157.6, 147.3, 136.0 (q, *J* = 33.0 Hz), 135.0, 130.5, 129.1, 128.1, 120.0, 125.2 (q, *J* = 4.0 Hz), 123.5 (q, *J* = 271.0 Hz), 123.0 (q, *J* = 3.0 Hz), 122.8, 34.6; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~16~H~11~F~3~N~2~O, 305.0896; found, 305.0895.

### 3-Methyl-2-(*p*-tolyl)-7-(trifluoromethyl)quinazolin-4(3*H*)-one (**3cc**) {#sec4.1.11}

It is obtained as waxy oil (174.3 mg, 55%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.42 (d, *J* = 8.3 Hz, 1H), 8.02 (s, 1H), 7.68 (d, *J* = 8.3 Hz, 1H), 7.47 (d, *J* = 8.1 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 3.54 (s, 3H), 2.45 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.2, 157.8, 147.6, 140.9, 135.9 (q, *J* = 32.7 Hz), 132.2, 129.7, 128.1, 128.0, 125.2 (q, *J* = 4.0 Hz), 123.6 (q, *J* = 272.0 Hz), 122.9 (q, *J* = 3.0 Hz), 122.8, 34.7, 21.5; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~17~H~13~F~3~N~2~O, 319.1053; found, 319.1058.

### 2-Phenyl-3-propylquinazolin-4(3*H*)-one (**3da**)^[@ref11]^ {#sec4.1.12}

It is obtained as a white solid (163.8 mg, 62%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.33 (d, *J* = 8.7 Hz, 1H), 7.78--7.70 (m, 2H), 7.54--7.46 (m, 6H), 3.93 (t, *J* = 7.6 Hz, 2H), 1.69--1.57 (m, 2H), 0.76 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.2, 156.3, 147.2, 135.7, 134.4, 129.9, 128.8, 127.8, 127.5, 127.0, 126.8, 121.0, 47.5, 22.2, 11.2; GC--MS *m*/*z*: 264 (M^+^).

### 3-Propyl-2-(*o*-tolyl)quinazolin-4(3*H*)-one (**3db**) {#sec4.1.13}

It is obtained as a white solid (180.9 mg, 65%); mp 89--91 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.34 (d, *J* = 8.1 Hz, 1H), 7.80--7.69 (m, 2H), 7.50 (t, *J* = 8.1 Hz, 1H), 7.44--7.28 (m, 4H), 4.18--4.06 (m, 1H), 3.51--3.39 (m, 1H), 2.23 (s, 3H), 1.74--1.42 (m, 2H), 0.74 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.1, 155.9, 147.4, 135.4, 135.0, 134.3, 130.7, 129.8, 127.8, 127.5, 127.0, 126.8, 126.2, 121.1, 47.0, 21.9, 19.3, 11.3; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~18~H~18~N~2~O, 279.1492; found, 279.1495.

### 3-Propyl-2-(*p*-tolyl)quinazolin-4(3*H*)-one (**3dc**)^[@ref11]^ {#sec4.1.14}

It is obtained as a white solid (197.6 mg, 71%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.32 (d, *J* = 7.9 Hz, 1H), 7.79--7.67 (m, 2H), 7.49 (t, *J* = 7.1 Hz, 1H), 7.41 (d, *J* = 8.0 Hz, 2H), 7.31 (d, *J* = 7.9 Hz, 2H), 3.95 (t, *J* = 8.0 Hz, 2H), 2.44 (s, 3H), 1.71--1.58 (m, 2H), 0.77 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.4, 156.6, 147.3, 140.0, 134.3, 132.9, 129.5, 127.8, 127.5, 126.9, 126.8, 121.0, 47.6, 22.2, 21.5, 11.3; GC--MS *m*/*z*: 278 (M^+^).

### 2-(4-Methoxyphenyl)-3-propylquinazolin-4(3*H*)-one (**3dd**) {#sec4.1.15}

It is obtained as a white solid (182.4 mg, 62%); mp 65--67 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.32 (d, *J* = 7.9 Hz, 1H), 7.77--7.68 (m, 2H), 7.52--7.44 (m, 3H), 7.02 (d, *J* = 8.7 Hz, 2H), 3.98 (t, *J* = 7.6 Hz, 2H), 3.88 (s, 3H), 1.70--1.56 (m, 2H), 0.78 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.5, 160.7, 156.3, 147.3, 134.3, 129.5, 128.2, 127.5, 126.95, 126.90, 120.9, 114.2, 55.6, 47.6, 22.2, 11.3; HRMS (ESI) *m*/*z* \[M + H\]^+^ calcd for C~18~H~18~N~2~O~2~, 295.1441; found, 295.1446.

### 2-(2-Iodophenyl)-3-propylquinazolin-4(3*H*)-one (**3df**) {#sec4.1.16}

It is obtained as a white solid (269.2 mg, 69%); mp 110--112 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.35 (d, *J* = 7.9 Hz, 1H), 7.94 (d, *J* = 8.0 Hz, 1H), 7.81--7.70 (m, 2H), 7.55--7.47 (m, 2H), 7.44 (d, *J* = 8.9 Hz, 1H), 7.20 (t, *J* = 7.7 Hz, 1H), 4.26--5.15 (m, 1H), 3.42--3.31 (m, 1H), 1.83--1.67 (m, 1H), 1.56--1.43 (m, 1H), 0.76 (t, *J* = 7.4 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.0, 156.2, 147.2, 140.3, 139.4, 134.4, 131.1, 129.2, 128.5, 127.6, 127.3, 126.9, 121.3, 96.4, 47.4, 22.0, 11.4; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~17~H~15~IN~2~O, 391.0302; found, 391.0308.

### 2-(2-Bromophenyl)-3-propylquinazolin-4(3*H*)-one (**3dg**) {#sec4.1.17}

It is obtained as a white solid (253.9 mg, 74%); mp 83--85 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.36 (d, *J* = 8.1 Hz, 1H), 7.80--7.72 (m, 2H), 7.70 (d, *J* = 8.0 Hz, 1H), 7.53 (t, *J* = 8.0 Hz, 1H), 7.49 (d, *J* = 4.4 Hz, 2H), 7.42--7.35 (m, 1H), 4.28--4.17 (m, 1H), 3.49--3.36 (m, 1H), 1.81--1.65 (m, 1H), 1.57--1.41 (m, 1H), 0.77 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 161.9, 154.5, 147.2, 136.5, 134.4, 133.1, 131.3, 129.9, 127.8, 127.6, 127.3, 126.9, 121.9, 121.3, 47.2, 22.0, 11.4; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~17~H~15~BrN~2~O, 343.0441; found, 343.0450.

### 8-Methyl-3-propyl-2-(*o*-tolyl)quinazolin-4(3*H*)-one (**3eb**) {#sec4.1.18}

It is obtained as a white liquid (222.2 mg, 76%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.20 (d, *J* = 8.0 Hz, 1H), 7.59 (d, *J* = 7.3 Hz, 1H), 7.43--7.29 (m, 5H), 4.16--4.04 (m, 1H), 3.57--3.34 (m, 1H), 2.57 (s, 3H), 2.25 (s, 3H), 1.74--1.40 (m, 2H), 0.74 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.6, 154.3, 146.1, 136.2, 135.7, 135.5, 134.8, 130.6, 129.6, 128.1, 126.5, 126.0, 124.4, 121.1, 47.0, 21.9, 19.5, 17.5, 11.3; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~19~H~20~N~2~O, 293.1648; found, 293.1650.

### 8-Methyl-3-propyl-2-(*p*-tolyl)quinazolin-4(3*H*)-one (**3ec**) {#sec4.1.19}

It is obtained as a white solid (236.8 mg, 81%); mp 91--93 °C ^1^H NMR (400 MHz, CDCl~3~): δ 8.17 (d, *J* = 7.9 Hz, 1H), 7.58 (d, *J* = 7.2 Hz, 1H), 7.44 (d, *J* = 8.0 Hz, 2H), 7.36 (t, *J* = 7.6 Hz, 1H), 7.31 (d, *J* = 7.9 Hz, 2H), 3.98 (t, *J* = 8 Hz, 2H), 2.58 (s, 3H), 2.45 (s, 3H), 1.68--1.57 (m, 2H), 0.77 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.9, 155.0, 146.1, 139.8, 136.1, 134.8, 133.4, 129.3, 128.2, 126.4, 124.4, 120.9, 47.5, 22.2, 21.5, 17.4, 11.2.; HRMS (ESI) *m*/*z*: \[M + H\]^+^ for C~19~H~20~N~2~O 293.1648, found, 293.1652.

### 2-Phenylquinazolin-4(3*H*)-one (**3fa**)^[@cit5j]^ {#sec4.1.20}

It is obtained as a white solid (140.0 mg, 63%); ^1^H NMR (400 MHz, CDCl~3~): δ 11.50 (s, 1H), 8.33 (d, *J* = 7.6 Hz, 1H), 8.28--8.20 (m, 2H), 7.88--7.77 (m, 2H), 7.64--7.56 (m, 3H), 7.51 (t, *J* = 7.2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 163.9, 151.8, 149.6, 135.0, 132.9, 131.8, 129.2, 128.1, 127.5, 126.9, 126.5, 121.0; GC--MS *m*/*z*: 222 (M^+^).

### 2-(*o*-Tolyl)quinazolin-4(3*H*)-one (**3fb**)^[@cit5j]^ {#sec4.1.21}

It is obtained as a white solid (153.5mg, 65%); ^1^H NMR (400 MHz, CDCl~3~): δ 10.42 (s, 1H), 8.26 (d, *J* = 8.0 Hz, 1H), 7.80 (d, *J* = 3.8 Hz, 2H), 7.56 (d, *J* = 7.2 Hz, 1H), 7.53--7.48 (m, 1H), 7.43 (t, *J* = 7.2 Hz, 1H), 7.38--3.31 (m, 2H), 2.53 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.9, 153.5, 149.1, 136.9, 135.0, 133.7, 131.6, 130.7, 128.7, 128.0, 127.1, 126.5, 126.4, 120.9, 20.2; GC--MS *m*/*z*: 236 (M^+^).

### 2-(4-Methoxyphenyl)quinazolin-4(3*H*)-one (**3fd**)^[@cit6i]^ {#sec4.1.22}

It is obtained as a white solid (151.3 mg, 60%); ^1^H NMR (400 MHz, CDCl~3~): δ 11.47 (br s, 1H), 8.32 (d, *J* = 7.9 Hz, 1H), 8.23 (d, *J* = 8.8 Hz, 2H), 7.83--7.73 (m, 2H), 7.52--7.42 (m, 1H), 7.07 (d, *J* = 8.7 Hz, 2H), 3.91 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 164.0, 162.5, 151.5, 149.8, 143.1, 134.9, 129.2, 127.9, 126.4, 125.2, 120.7, 114.5, 55.6; GC--MS *m*/*z*: 252 (M^+^).

### 2-(Naphthalen-2-yl)quinazolin-4(3*H*)-one (**3fe**) {#sec4.1.23}

It is obtained as a white solid (185.1 mg, 68%); mp 211--213 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 12.67 (s, 1H), 8.83 (s, 1H), 8.31 (d, *J* = 8.6 Hz, 1H), 8.19 (d, *J* = 7.8 Hz, 1H), 8.10--7.98 (m, 3H), 7.87 (t, *J* = 7.5 Hz, 1H), 7.80 (d, *J* = 8.0 Hz, 1H), 7.69--7.59 (m, 2H), 7.54 (t, *J* = 7.4 Hz, 1H); ^13^C NMR (100 MHz, DMSO-*d*~6~): δ 162.3, 152.3, 148.7, 134.6, 134.1, 132.2, 129.9, 128.9, 128.2, 128.1, 127.9, 127.6, 127.4, 126.9, 126.6, 125.9, 124.5, 121.0; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~18~H~12~N~2~O, 273.1022; found, 273.1028.

### 3-Methyl-2-(thiophen-2-yl)quinazolin-4(3*H*)-one (**3ah**)^[@cit6d]^ {#sec4.1.24}

It is obtained as a white solid (133.2 mg, 55%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.29 (d, *J* = 8.0 Hz, 1H), 7.77--7.67 (m, 2H), 7.55 (d, *J* = 5.0 Hz, 1H), 7.53--7.44 (m, 2H), 7.16 (t, *J* = 4.0 Hz, 1H), 3.77 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~) δ.162.8, 150.1, 147.3, 137.2, 134.4, 129.8, 129.5, 127.5, 127.1, 126.8, 120.2, 34.2; GC--MS *m*/*z*: 242 (M^+^).

### 2-(Thiophen-2-yl)quinazolin-4(3*H*)-one (**3fh**)^[@cit5j]^ {#sec4.1.25}

It is obtained as a white solid (141.2 mg, 62%); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 12.65 (s, 1H), 8.23 (d, *J* = 3.5 Hz, 1H), 8.12 (d, *J* = 7.7 Hz, 1H), 7.86 (d, *J* = 4.9 Hz, 1H), 7.79 (t, *J* = 7.4 Hz, 1H), 7.64 (d, *J* = 8.1 Hz, 1H), 7.48 (t, *J* = 7.5 Hz, 1H), 7.23 (t, *J* = 4.3 Hz, 1H); ^13^C NMR (100 MHz, DMSO-*d*~6~): δ 161.8, 148.6, 147.8, 137.3, 134.6, 132.1, 129.4, 128.5, 126.8, 126.3, 125.9, 120.8; GC--MS *m*/*z*: 228 (M^+^).

### 2-(Pyridin-2-yl)quinazolin-4(3*H*)-one (**3fi**)^[@cit6i]^ {#sec4.1.26}

It is obtained as a white solid (154.0 mg, 69%); ^1^H NMR (400 MHz, CDCl~3~): δ 10.96 (s, 1H), 8.68 (d, *J* = 4.4 Hz, 1H), 8.59 (d, *J* = 7.9 Hz, 1H), 8.36 (d, *J* = 7.9 Hz, 1H), 7.92 (t, *J* = 7.7 Hz, 1H), 7.86--7.76 (m, 2H), 7.56--7.4 (m, 2H); ^13^C NMR (100 MHz, CDCl~3~): δ 161.5, 149.2, 149.0, 148.8, 148.5, 137.6, 134.7, 128.1, 127.4, 126.9, 126.3. 122.6, 122.1; GC--MS *m*/*z*: 223 (M^+^).

### 2,3-Dimethylquinazolin-4(3*H*)-one (**3aj**)^[@cit5h]^ {#sec4.1.27}

It is obtained as a white solid (135.8 mg, 78%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.58 (d, *J* = 7.9 Hz, 1H), 8.04 (t, *J* = 8.3 Hz, 1H), 7.93 (d, *J* = 8.1 Hz, 1H), 7.76 (t, *J* = 7.5 Hz, 1H), 3.95 (s, 3H), 2.94 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.4, 154.5, 147.3, 134.2, 126.8, 126.7, 126.4, 120.3, 31.1, 23.7; GC--MS *m*/*z*: 174 (M^+^).

### 2-Methyl-3-(*o*-tolyl)quinazolin-4(3*H*)-one (**3gj**, Methaqualone)^[@ref11]^ {#sec4.1.28}

It is obtained as a white solid (167.5 mg, 67%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.28 (d, *J* = 7.9 Hz, 1H), 7.77 (t, *J* = 7.5 Hz, 1H), 7.69 (d, *J* = 8.1 Hz, 1H), 7.46 (t, *J* = 7.5 Hz, 1H), 7.41--7.33 (m, 3H), 7.15 (d, *J* = 7.3 Hz, 1H), 2.18 (s, 3H), 2.12 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 161.7, 154.4, 147.7, 136.9, 135.4, 134.6, 129.6, 128.0, 127.7, 127.2, 126.8, 126.6, 120.8, 23.9, 17.4; GC--MS *m*/*z*: 250 (M^+^).

### 2-(2-Fluorophenyl)quinazolin-4(3*H*)-one (**3f**)^[@cit5j]^ {#sec4.1.29}

It is obtained as a white solid (110.4 mg, 92%); ^1^H NMR (400 MHz, CDCl~3~): δ 10.68 (s, 1H), 8.25 (d, *J* = 7.9 Hz, 1H), 8.20 (t, *J* = 7.8 Hz, 1H), 7.81--7.71 (m, 2H), 7.54--7.44 (m, 2H), 7.29 (t, *J* = 7.6 Hz, 1H), 7.23--7.14 (m, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 162.3, 160.7 (d, *J* = 249.0 Hz), 149.0, 148.6 (d, *J* = 10.0 Hz), 134.8, 133.4 (d, *J* = 9.0 Hz), 131.3 (d, *J* = 1.0 Hz), 128.0, 127.2, 126.5, 125.1 (d, *J* = 3.0 Hz), 121.2, 120.1 (d, *J* = 10.0 Hz), 116.6 (d, *J* = 22.0 Hz); GC--MS *m*/*z*: 240 (M^+^).

### 2-Benzamido-*N*-methylbenzamide (**4aa**) {#sec4.1.30}

It is obtained as a light yellow solid; mp 163--165 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 12.08 (s, 1H), 8.66 (d, *J* = 8.5 Hz, 1H), 8.02 (d, *J* = 7.4 Hz, 2H), 7.64--7.37 (m, 5H), 6.95 (t, *J* = 7.6 Hz, 1H), 6.85 (br s, 1H), 2.99 (d, *J* = 4.8 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 169.9, 165.9, 139.5, 134.8, 132.3, 132.0, 128.9, 127.4, 126.8, 123.0, 121.6, 120.9, 26.9; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~15~H~14~N~2~O~2~, 255.1128; found, 255.1125.
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